The role of BDNF in depression on the basis of its location in the neural circuitry

Acta Pharmacologica Sinica

Volumn 32, Issue 1, 2011, Pages 3-11

  Yu, Hui ^a   Chen, Zhe Yu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

antidepressant; BDNF; depression; neural circuitry

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; COCAINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; HALOPERIDOL; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MORPHINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYGDALOID NUCLEUS; BIPOLAR DISORDER; DEPRESSION; DNA POLYMORPHISM; DRUG ACTIVITY; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; MANIA; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; SIGNAL TRANSDUCTION;

EID: 78651076464     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.184     Document Type: Review

References (103)

1. Briley M, Moret C. Present and future anxiolytics. IDrugs 2000; 3: 695-9.
2. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
3. Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28: 335-41.
4. Burmeister M. Basic concepts in the study of diseases with complex genetics. Biol Psychiatry 1999; 45: 522-32.
5. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.
6. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: A dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004; 7: 193-218.
7. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732-9.
8. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20: 59-61.
9. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398: 215-9.
10. Palomino A, Vallejo-Illarramendi A, Gonzalez-Pinto A, Aldama A, Gonzalez-Gomez C, Mosquera F, et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006; 86: 321-2.
11. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24: 4401-11.
12. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activitydependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-69.
13. Post RM. Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications. J Psychiatr Res 2007; 41: 979-90.
14. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007; 61: 187-97.
15. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T, et al. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 2005; 180: 95-9.
16. Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, et al. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry 2001; 6: 83-6.
17. Mirowska-Guzel D, Mach A, Gromadzka G, Czlonkowski A, Czlonkowska A. BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the Polish population. Gender differences. J Neuroimmunol 2008; 193: 170-2.
18. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-27.
19. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140-3.
20. Yu H, Wang Y, Pattwell S, Jing D, Liu T, Zhang Y, et al. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci 2009; 29: 4056-64.
21. Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 2008; 117: 30-51.
22. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88-109.
23. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci 2006; 7: 137-51.
24. Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007; 12: 1079-88.
25. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007; 10: 1089-93.
26. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007; 7: 18-21.
27. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 2005; 11: 1495-510.
28. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-8.
29. Ongur D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex 2000; 10: 206-19.
30. Chamberlain SR, Sahakian BJ. The neuropsychology of mood disorders. Curr Psychiatry Rep 2006; 8: 458-63.
31. Davidson RJ, Abercrombie H, Nitschke JB, Putnam K. Regional brain function, emotion and disorders of emotion. Curr Opin Neurobiol 1999; 9: 228-34.
32. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12: 2-19.
33. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-13.
34. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516-8.
35. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-5.
36. Baumann B, Danos P, Krell D, Diekmann S, Leschinger A, Stauch R, et al. Reduced volume of limbic system-affiliated basal ganglia in mood disorders: Preliminary data from a postmortem study. J Neuropsychiatry Clin Neurosci 1999; 11: 71-8.
37. Lacerda AL, Nicoletti MA, Brambilla P, Sassi RB, Mallinger AG, Frank E, et al. Anatomical MRI study of basal ganglia in major depressive disorder. Psychiatry Res 2003; 124: 129-40.
38. Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jager M, Groll C, et al. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry 2003; 53: 338-44.
39. Siegle GJ, Konecky RO, Thase ME, Carter CS. Relationships between amygdala volume and activity during emotional information processing tasks in depressed and never-depressed individuals: An fMRI investigation. Ann N Y Acad Sci 2003; 985: 481-4.
40. LaBar KS, Cabeza R. Cognitive neuroscience of emotional memory. Nat Rev Neurosci 2006; 7: 54-64.
41. Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991; 12: 118-34.
42. Videbech P, Ravnkilde B. Hippocampal volume and depression: A meta-analysis of MRI studies. Am J Psychiatry 2004; 161: 1957-66.
43. Lucassen PJ, Muller MB, Holsboer F, Bauer J, Holtrop A, Wouda J, et al. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 2001; 158: 453-68.
44. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004; 56: 640-50.
45. Aydemir C, Yalcin ES, Aksaray S, Kisa C, Yildirim SG, Uzbay T, et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1256-60.
46. Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF level in depressive patients. J Affect Disord 2007; 101: 239-44.
47. Dwivedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, Roberts RC, et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 273-82.
48. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 78-85.
49. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-5.
50. Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 2001; 98: 12796-801.
51. Rasmusson AM, Shi L, Duman R. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology 2002; 27: 133-42.
52. Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry 2004; 55: 708-14.
53. Li WJ, Yu H, Yang JM, Gao J, Jiang H, Feng M, et al. Anxiolytic effect of music exposure on BDNFMet/Met transgenic mice. Brain Res 2010; 1347: 71-9.
54. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 2004; 29: 2189-99.
55. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47.
56. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003; 45: 553-63.
57. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519-25.
58. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressantinduced behavioral effects. J Neurosci 2003; 23: 349-57.
59. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressantlike effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-7.
60. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-8.
61. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brainderived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-61.
62. Duman RS. Pathophysiology of depression: The concept of synaptic plasticity. Eur Psychiatry 2002; 17: 306-10.
63. Widnell KL, Russell DS, Nestler EJ. Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro. Proc Natl Acad Sci USA 1994; 91: 10947-51.
64. Malberg JE, Blendy JA. Antidepressant action: To the nucleus and beyond. Trends Pharmacol Sci 2005; 26: 631-8.
65. Fujioka T, Fujioka A, Duman RS. Activation of cAMP signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. J Neurosci 2004; 24: 319-28.
66. Arthur JS, Fong AL, Dwyer JM, Davare M, Reese E, Obrietan K, et al. Mitogen- and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins. J Neurosci 2004; 24: 4324-32.
67. Tyler WJ, Perrett SP, Pozzo-Miller LD. The role of neurotrophins in neurotransmitter release. Neuroscientist 2002; 8: 524-31.
68. Mizuno K, Giese KP. Hippocampus-dependent memory formation: Do memory type-specific mechanisms exist? J Pharmacol Sci 2005; 98: 191-7.
69. Zald DH. Orbital versus dorsolateral prefrontal cortex: Anatomical insights into content versus process differentiation models of the prefrontal cortex. Ann N Y Acad Sci 2007; 1121: 395-406.
70. Barbas H. Connections underlying the synthesis of cognition, memory, and emotion in primate prefrontal cortices. Brain Res Bull 2000; 52: 319-30.
71. Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, et al. Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry 2007; 62: 429-37.
72. Galynker II, Cai J, Ongseng F, Finestone H, Dutta E, Serseni D. Hypofrontality and negative symptoms in major depressive disorder. J Nucl Med 1998; 39: 608-12.
73. Wagner G, Sinsel E, Sobanski T, Kohler S, Marinou V, Mentzel HJ, et al. Cortical inefficiency in patients with unipolar depression: An event-related FMRI study with the Stroop task. Biol Psychiatry 2006; 59: 958-65.
74. Castren E. Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol 2004; 4: 58-64.
75. Dwivedi Y, Rizavi HS, Zhang H, Mondal AC, Roberts RC, Conley RR, et al. Neurotrophin receptor activation and expression in human postmortem brain: Effect of suicide. Biol Psychiatry 2009; 65: 319-28.
76. Brown J, Cooper-Kuhn CM, Kempermann G, Van Praag H, Winkler J, Gage FH, et al. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci 2003; 17: 2042-6.
77. Brown SM, Henning S, Wellman CL. Mild, short-term stress alters dendritic morphology in rat medial prefrontal cortex. Cereb Cortex 2005; 15: 1714-22.
78. Burton CL, Chatterjee D, Chatterjee-Chakraborty M, Lovic V, Grella SL, Steiner M, et al. Prenatal restraint stress and motherless rearing disrupts expression of plasticity markers and stress-induced corticosterone release in adult female Sprague-Dawley rats. Brain Res 2007; 1158: 28-38.
79. Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry 2009; 65: 760-9.
80. Kozisek ME, Middlemas D, Bylund DB. The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment. Neuropharmacology 2008; 54: 251-7.
81. Sairanen M, O'Leary OF, Knuuttila JE, Castren E. Chronic antidepressant treatment selectively increases expression of plasticityrelated proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience 2007; 144: 368-74.
82. Qi X, Lin W, Li J, Li H, Wang W, Wang D, et al. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 2008; 31: 278-85.
83. Price JL, Carmichael ST, Drevets WC. Networks related to the orbital and medial prefrontal cortex; a substrate for emotional behavior? Prog Brain Res 1996; 107: 523-36.
84. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21: 467-76.
85. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 2005; 58: 843-53.
86. Eisch AJ, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression. Biol Psychiatry 2003; 54: 994-1005.
87. Pliakas AM, Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlezon WA, Jr. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response elementbinding protein expression in nucleus accumbens. J Neurosci 2001; 21: 7397-403.
88. Carlezon WA Jr, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, et al. Regulation of cocaine reward by CREB. Science 1998; 282: 2272-5.
89. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-9.
90. Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: From animal models to human behavior. Neuron 2005; 48: 175-87.
91. Quiroz JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: Clues from the molecular pathophysiology. Mol Psychiatry 2004; 9: 756-76.
92. Yaniv D, Desmedt A, Jaffard R, Richter-Levin G. The amygdala and appraisal processes: Stimulus and response complexity as an organizing factor. Brain Res Brain Res Rev 2004; 44: 179-86.
93. Brambilla P, Harenski K, Nicoletti M, Sassi RB, Mallinger AG, Frank E, et al. MRI investigation of temporal lobe structures in bipolar patients. J Psychiatr Res 2003; 37: 287-95.
94. Frangou S. The maudsley bipolar disorder project. Epilepsia 2005; 46: 19-25.
95. Mah L, Zarate CA Jr, Singh J, Duan YF, Luckenbaugh DA, Manji HK, et al. Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry 2007; 61: 765-75.
96. Vyas A, Mitra R, Shankaranarayana Rao BS, Chattarji S. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci 2002; 22: 6810-8.
97. Pawlak R, Rao BS, Melchor JP, Chattarji S, McEwen B, Strickland S. Tissue plasminogen activator and plasminogen mediate stressinduced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci USA 2005; 102: 18201-6.
98. Conrad CD, LeDoux JE, Magarinos AM, McEwen BS. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav Neurosci 1999; 113: 902-13.
99. Pizarro JM, Lumley LA, Medina W, Robison CL, Chang WE, Alagappan A, et al. Acute social defeat reduces neurotrophin expression in brain cortical and subcortical areas in mice. Brain Res 2004; 1025: 10-20.
100. Fanous S, Hammer RP Jr, Nikulina EM. Short- and long-term effects of intermittent social defeat stress on brain-derived neurotrophic factor expression in mesocorticolimbic brain regions. Neuroscience 2010; 167: 598-607.
101. Govindarajan A, Rao BS, Nair D, Trinh M, Mawjee N, Tonegawa S, et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci USA 2006; 103: 13208-13.
102. Vyas A, Pillai AG, Chattarji S. Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior. Neuroscience 2004; 128: 667-73.
103. Mitra R, Jadhav S, McEwen BS, Vyas A, Chattarji S. Stress duration modulates the spatiotemporal patterns of spine formation in the basolateral amygdala. Proc Natl Acad Sci USA 2005; 102: 9371-6.